CUG-252 / Cugene, AbbVie - LARVOL DELTA

CUG252, a Treg-Selective IL-2, Resets Immune Tolerance and Drives Early Clinical Improvement in Patients with Systemic Lupus Erythematosus (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • IL2

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Cugene Inc. | Active, not recruiting ➔ Completed

Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Cugene Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2024 ➔ Apr 2025 | Trial primary completion date: Jul 2024 ➔ Apr 2025

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Cugene Inc. | Active, not recruiting ➔ Completed

Trial completion • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Cugene Inc.

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Cugene Inc. | N=88 ➔ 32

Enrollment change • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Study of CUG252 in Healthy Volunteers and in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=88 | Active, not recruiting | Sponsor: Cugene Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

"Has the been any clinical data reported for the molecule (CUG252)?" (,@WSceptor)

Clinical data

Study of CUG252 in Healthy Volunteers and in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: Cugene Inc.

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus